1. Report Overview

1.1 Global Gene Therapy Market Overview

1.2 Benefits of This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report

1.5 Who is This Report For?

1.6 Methods of the Study

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to Gene Therapy

2.1 What is Gene Therapy?

2.2 Types of Gene Therapy

2.3 Products Excluded from the Report

2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2016-2027

3.1 The World Market for Gene Therapy: Overview of Products

3.2 Gendicine (rAd-p53) – The First Gene Therapy to Market

3.3 Oncorine: Growth is Hindered by Certain Factors

3.4 Neovasculgen: Russia’s First Gene Therapy

3.4.1 Neovasculgen: Historical Performance and Revenue Forecast, 2016-2027

3.5 Glybera: A Drug with Promise

3.5.1 Glybera: Pricing Ends the Dream to Become a Blockbuster Product

4. Gene Therapy World Market and Disease Submarkets, 2016-2027

4.1 The Global Market for Gene Therapy Drug Treatments in 2016

4.2 Gene Therapy Market Forecast, 2016-2027

4.3 Gene Therapy for Cancer

4.3.1 Clinical Trials for Cancer

4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2016-2027

4.4 Gene Therapy for Rare Diseases

4.4.1 The Rare Disease Treatment Submarket Forecast 2016-2027

4.5 Gene Therapy for Cardiovascular Diseases

4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2016-2027

4.6 Gene Therapy for Ophthalmologic Diseases

4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases

4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2016-2027

4.7 Gene Therapy for Other Diseases

4.7.1 The Other Disease Treatment Submarket Forecast 2016-2027

4.8 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

5. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

5.1 UniQure- the First Commercial Stage Gene Therapy Company in the West

5.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies

5.3 Bluebird Bio: Gene Editing Technology

5.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US

5.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases

5.6 Oxford Biomedica: Collaboration as a Strategy

5.7 GenSight Biologics - Novel Mitochondrial Technology Platform

5.8 Gene Therapy and Big Pharma: Collaborations

6. R&D Pipeline Analysis and Forecasts, 2016-2027

6.1 Pipeline

6.2 Pipeline Analysis

6.3 GSK2696273 – GSK

6.4 Collategene (AMG0001) - AnGes MG/Vical

6.5 BC-819 - BioCancell

6.6 BC-821 - BioCancell

6.7 Lenti-D - Bluebird Bio

6.8 LentiGlobin (LentiGlobin BB305) - Bluebird Bio

6.9 SPK-RPE65 - Spark Therapeutics

6.10 SPK-CHM - Spark Therapeutics

6.11 SPK-FIX - Spark Therapeutics/Pfizer

6.12 SPK-TPP1- Spark Therapeutics

6.13 Invossa (TissueGene-C) - TissueGene Inc/Kolon Life Science

6.14 VM202-DPN - ViroMed

6.15 Important Pipeline Technology Developments

6.16 The Future of the Gene Therapy Pipeline

7. Qualitative Analysis of the Gene Therapy Market, 2017-2027

7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2017

7.2 Strengths: A Vast Pipeline for a Wide Range of Indications

7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth

7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2017-2027

7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way

7.6 Threats: Expensive Drugs with Strict Regulations

7.7 National Markets: Regulation of the Gene Therapy Market

7.7.1 Gene Therapy Regulations: Evolving with the Market

7.7.2 US Regulations: Strict Regulation of a Cautious Market

7.7.3 EU Regulations: One Approval So Far

7.7.4 Japanese Regulations: A Rigorous Process

8. Conclusions

8.1 The World Gene Therapy Treatment Market: Current World Outlook

8.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2016-2027

8.1.2 Driver for Growth to 2027: A Vast Pipeline of Gene Therapy Products

8.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success

8.2 The Future of the Gene Therapy Treatment Market

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2015, 2016, and 2017

Table 3.1 Approved Gene Therapies, 2016

Table 3.2 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2016

Table 3.3 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2016

Table 4.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2016-2027

Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2016

Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2016

Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2016

Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2016

Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2016

Table 4.8 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2016

Table 4.9 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2016

Table 4.10 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2016

Table 4.11 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 4.12 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2017

Table 4.13 Rare Diseases Gene Therapy Pipeline, 2016

Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 4.15 Cardiovascular Gene Therapy Pipeline, 2016

Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 4.17 Preclinical Ophthalmologic Pipeline, 2016

Table 4.18 Clinical Ophthalmologic Pipeline, 2016

Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2016

Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2016-2021

Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2022-2027

Table 5.1 uniQure Pipeline, 2016

Table 5.2 Spark Therapeutics Collaborations, 2016

Table 5.3 Selected Big Pharma Collaborations in Gene Therapy, 2016

Table 6.1 Promising Gene Therapies in Development, 2016

Table 6.2 Gene Therapies in Phase 3, 2016

Table 6.3 GSK2696273 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 6.4 Collategene Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 6.5 BC-819 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 6.6 Lenti-D Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 6.7 SPK-RPE65 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 6.8 Invossa Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027

Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2017

Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2016

Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2016

Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2016

Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2016

Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2017

Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2016

Table 8.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2016, 2021 and 2027

List of Figures

Figure 1.1 Global Gene Therapy Treatment Market Segmentation Overview, 2016

Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2016

Figure 3.1 Neovasculgen Forecast, Revenue ($m), 2016-2027

Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2016-2027

Figure 4.2 Cancer Gene Therapy Pipeline by Phase of Development, 2016

Figure 4.3 Global Gene Therapy Market: Market Shares (%) by Indication, 2016

Figure 4.4 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2016-2027

Figure 4.5 Global Gene Therapy Market: Market Shares (%) by Indication, 2017

Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2016

Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2016-2027

Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2016

Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2016-2027

Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2016-2027

Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2016-2027

Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2021

Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2027

Figure 6.1 Gene Therapies in Clinical Development by Phase, 2016

Figure 6.2 GSK2696273 Forecast, Revenue ($m), 2016-2027

Figure 6.3 Collategene Forecast, Revenue ($m), 2016-2027

Figure 6.4 BC-819 Forecast, Revenue ($m), 2016-2027

Figure 6.5 Lenti-D Forecast, Revenue ($m), 2016-2027

Figure 6.6 SPK-RPE65 Forecast, Revenue ($m), 2016-2027

Figure 6.7 Invossa Forecast, Revenue ($m), 2016-2027

Figure 8.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2016, 2021, and 2027